^
    Back
    Association details:
    Biomarker:CD79B mutation
    Cancer:Diffuse Large B Cell Lymphoma
    Drug:Brukinsa (zanubrutinib) (BTK inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: C2 – Inclusion Criteria
    Source:
    clinicaltrials.gov
    Title:

    Treatment of CD79B Mutant Relapsed/Refractory Diffuse Large B-Cell Lymphoma With Bruton Tyrosine Kinase Inhibitor Zanubrutinib

    Excerpt:
    ...Positive CD79B mutation confirmed by the central laboratory....
    Trial ID:
    BGB-3111-218
    Evidence Level:
    Sensitive: C3 – Early Trials
    Source:
    EHA 2020
    Title:

    BIOMARKER IDENTIFICATION IN RELAPSED/REFRACTORY NON-GERMINAL CENTER B-CELL–LIKE DIFFUSE LARGE B-CELL LYMPHOMA TREATED WITH ZANUBRUTINIB

    Published date:
    06/12/2020
    Excerpt:
    The retrospective biomarker analysis identified subsets of patients (such as PAX5 high or with CD79B mutations) with higher response rates to zanubrutinib treatment.